Resistance Mechanisms in ROS1-Positive Lung Cancer: New Insight into a Rare but Clinically Important Entity

被引：2
|
作者：
von Itzstein, Mitchell S. [1 ,2 ]
Gerber, David E. [1 ,2 ,3 ,4 ]
机构：
[1] Univ Texas Southwestern Med Ctr, Dept Internal Med, Div Hematol Oncol, Dallas, TX USA
[2] Univ Texas Southwestern Med Ctr, Harold C Simmons Canc Ctr, Dallas, TX USA
[3] Univ Texas Southwestern Med Ctr, Peter ODonnell Jr Sch Publ Hlth, Dallas, TX USA
[4] Univ Texas Southwestern Med Ctr, Div Hematol Oncol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA
来源：
CLINICAL CHEMISTRY | 2024年 / 70卷 / 04期
关键词：
D O I：
10.1093/clinchem/hvae021
中图分类号：
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号：
1001 ;
摘要：
引用
收藏
页码：571 / 573
页数：3
相关论文
共 50 条
  • [1] Resistance Mechanisms in ROS1-Positive Lung Cancer: New Insight into a Rare but Clinically Important Entity (vol 70, pg 571, 2024)
    von Itzstein, Mitchell S.
    Gerber, David E.
    CLINICAL CHEMISTRY, 2024, 70 (06) : 890 - 890
  • [2] Resistance mechanisms and potent-targeted therapies of ROS1-positive lung cancer
    Roys, Annie
    Chang, Xing
    Liu, Yang
    Xu, Xiaobo
    Wu, Yingliang
    Zuo, Daiying
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2019, 84 (04) : 679 - 688
  • [3] Resistance mechanisms and potent-targeted therapies of ROS1-positive lung cancer
    Annie Roys
    Xing Chang
    Yang Liu
    Xiaobo Xu
    Yingliang Wu
    Daiying Zuo
    Cancer Chemotherapy and Pharmacology, 2019, 84 : 679 - 688
  • [4] Lorlatinib: a new treatment option for ROS1-positive lung cancer
    Duruisseaux, Michael
    LANCET ONCOLOGY, 2019, 20 (12): : 1622 - 1623
  • [5] Metaanalysis of ROS1-positive lung cancer cases
    Zinsky, Rica
    EUROPEAN RESPIRATORY JOURNAL, 2016, 48
  • [6] An Activating KIT Mutation Induces Crizotinib Resistance in ROS1-Positive Lung Cancer
    Dziadziuszko, Rafal
    Le, Anh T.
    Wrona, Anna
    Jassem, Jacek
    Camidge, D. Ross
    Varella-Garcia, Marileila
    Aisner, Dara L.
    Doebele, Robert C.
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (08) : 1273 - 1281
  • [7] Patterns of Metastatic Spread and Mechanisms of Resistance to Crizotinib in ROS1-Positive Non-Small-Cell Lung Cancer
    Gainor, Justin F.
    Tseng, Diane
    Yoda, Satoshi
    Dagogo-Jack, Ibiayi
    Friboulet, Luc
    Lin, Jessica J.
    Hubbeling, Harper G.
    Dardaei, Leila
    Farago, Anna F.
    Schultz, Katherine R.
    Ferris, Lorin A.
    Piotrowska, Zofia
    Hardwick, James
    Huang, Donghui
    Mino-Kenudson, Mari
    Iafrate, A. John
    Hata, Aaron N.
    Yeap, Beow Y.
    Shaw, Alice T.
    JCO PRECISION ONCOLOGY, 2017, 1
  • [8] Hippo-YAP Pathway Mediated Resistance to Crizotinib in ROS1-Positive Lung Cancer
    Sun, P.
    Gao, H.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (12) : S1075 - S1075
  • [9] Hippo-YAP pathway mediated resistance to crizotinib in ROS1-positive lung cancer
    Sun, P.
    Gao, H.
    ANNALS OF ONCOLOGY, 2018, 29
  • [10] Frequency and spectrum of ROS1 resistance mutations in ROS1-positive lung cancer patients progressing on crizotinib.
    Gainor, Justin F.
    Friboulet, Luc
    Yoda, Satoshi
    Alghalandis, Leila Dardaei
    Farago, Anna F.
    Logan, Jennifer
    Schultz, Katherine
    Sequist, Lecia V.
    Engelman, Jeffrey A.
    Shaw, Alice Tsang
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
12345